Telix Pharmaceuticals Faces SEC Investigation and FDA Setbacks

As investors in Telix Pharmaceuticals Limited witnessed a sharp decline in the price of their American Depositary Shares, the company faced a series of setbacks that have raised concerns over its transparency and corporate accountability. On August 28, 2025, Telix revealed that the FDA sought additional data on its drug to detect a form of kidney cancer, causing a 16% drop in ADS prices. This development follows a subpoena received by Telix from the SEC on July 22, 2025, which drove down ADS prices by 10% the next day. The national shareholders' rights firm Hagens Berman is investigating whether Telix may have misled investors about certain of its drug candidates, urging investors to come forward with substantial losses.

Key Takeaways:

• Telix Pharmaceuticals Limited received a subpoena from the SEC on July 22, 2025, related to its disclosures about prostate cancer therapeutic candidates.
• The company's American Depositary Shares (ADSs) fell 10% after the SEC subpoena was revealed.
• Telix said on August 28, 2025, that it received a Complete Response Letter from the FDA for its Biologics License Application for Zircaix(R), which is intended to diagnose and characterize renal masses as clear cell renal cell carcinoma.
• The CRL identified deficiencies in chemistry, manufacturing, and controls and requested additional data to establish comparability of the drug product used in the phase 3 clinical trial and the manufacturing process intended for commercial use.
• The FDA also documented notices of deficiency issued to Telix's third-party manufacturing and supply chain partners that must be remediated.
• Hagens Berman is investigating whether Telix may have misled investors about the development and commercial prospects of its candidates.
• The investigation is focused on the propriety of Telix's statements concerning certain of its prostate cancer therapeutic candidates and also statements concerning its other drug candidates.
• Reed Kathrein, partner at Hagens Berman, stated that the firm is investigating whether Telix may have misled investors about the development and commercial prospects of its candidates.
• Whistleblowers with non-public information about Telix may receive up to 30% of any successful recovery made by the SEC under the SEC Whistleblower program.

Statistics:

• Telix ADSs fell 16% on August 28, 2025, after the FDA sought additional data on its drug to detect a form of kidney cancer.
• The price of Telix ADSs dropped 10% the day after the SEC subpoena was revealed on July 22, 2025.
• The total losses to Telix investors are still unknown, but Hagens Berman is investigating substantial losses.
• Hagens Berman has secured over $2.9 billion in corporate accountability cases.

Sources:

• GlobeNewswire: "Telix Pharmaceuticals Limited (TLX) Investigation: Hagens Berman Continues to Investigate Telix on Behalf of Investors in NASDAQ: TLX"
• GlobeNewswire: "Telix Pharmaceuticals Limited (TLX) Investigation: Hagens Berman Continues to Investigate Telix on Behalf of Investors in NASDAQ: TLX"
• COMTEX_468886422/2010/2025-09-19T08:30:01